Gastric Cancer Clinical Trials in Grand Rapids, Michigan

7 studies are recruiting for gastric cancer in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Grand Rapids, Michigan

   Locations

   311 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

2. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Grand Rapids, Michigan

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

3. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

4. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

5. Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

   This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, Grand Rapids, Michigan

   Locations

   44 in total

   Run by

   AstraZeneca

   See if you can join NCT05702229 on ClinicalTrials.gov

6. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

   This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   6 in total

   Run by

   Tanabe Pharma America, Inc.

   See if you can join NCT06943521 on ClinicalTrials.gov

7. 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

   This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patient…

   Stage

   Phase 1

   Ages

   15 and older

   Site

   BAMF Health, Inc., Grand Rapids, Michigan

   Locations

   5 in total

   Run by

   Lantheus Medical Imaging

   See if you can join NCT06298916 on ClinicalTrials.gov